Glenmark Pharmaceuticals Ltd operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Glenmark Pharmaceuticals Ltd with three other
companies in this sector in India:
Piramal Enterprises Limited
sales of 85.04 billion Indian Rupees [US$1.34 billion]
of which 47%
Cadila Healthcare Ltd
(94.30 billion Indian Rupees [US$1.48 billion]
of which 100%
was Pharmaceutical Products), and
Jubilant Life Sciences Limited
(58.61 billion Indian Rupees [US$922.59 million]
of which 53%
During the year ended March of 2017, sales at
Glenmark Pharmaceuticals Ltd were 91.86 billion Indian Rupees (US$1.45 billion).
increase of 20.3%
versus 2016, when the company's sales were 76.34 billion Indian Rupees.
This was the fifth consecutive year of sales increases at Glenmark Pharmaceuticals Ltd
(and since 2012, sales have increased a total of 128%).